

Ain Shams University
Faculty of Science
Department of Biochemistry



**Development of Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) candidate vaccine**

THESIS

Submitted for the Degree of PhD in Science
(Biochemistry)

By

Mahmoud Mohamed Mostafa Shehata
(M.Sc. Biochemistry / 2012)

SUPERVISION COMMITTEE

Prof. Dr. Ahmed Osman Egiza

Professor of Biochemistry
Department of Biochemistry
Faculty of Science - Ain Shams University

Prof. Dr. Mohamed Ahmed Ali

Professor of Virology
Environmental Research Division
National Research Centre

Dr. Mohamed Ghazi Kayali

Assistant Professor of Virology
Department of Epidemiology and Human
Genetics - University of Texas

Department of Biochemistry

Faculty of Science
Ain Shams University
EGYPT

2018

APPROVAL SHEET

Development of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) candidate vaccine

Thesis

**Submitted for the Degree of Doctor of Philosophy in
Science (Biochemistry)**

By

MAHMOUD MOHAMED MOSTAFA SHEHATA

APPROVAL COMMITTEE

Prof. Dr. Ahmed Osman Egiza.....
Professor of Biochemistry, Department of Biochemistry, Faculty
Science Ain Shams University

Prof. Dr. Mohamed Ahmed Ali.....
Professor of Virology Water Pollution Research Department,
National Research Centre

Prof. Dr.
Professor of

Prof. Dr.
Professor of

Date of examination: / /2018

**This thesis has not been previously
submitted for any degree at this or at
any university.**

Mahmoud Shehata

DEDICATION

I dedicate this work with all my deepest love and appreciation to all my family especially my awesome father, my lovely mother, my sisters, my father in law, my mother in law, my aunts, my uncles, my brothers in law, my sisters in law and my lovely wife for their love, patience, care, help and permanent encouragements during my study and for helping me throughout my life.

“Praise to Allah for choosing you to be my family”

ACKNOWLEDGEMENT

At first, a pray thanks to my merciful Allah for giving me the ability and enthusiasm to complete this work and for granting me with the most respectable and great supervisors.

*I would like to thank **Prof. Dr. Ahmed Osman Egiza** Professor of Biochemistry, Department of Biochemistry, Faculty of Science, Ain Shams University for his kind supervision and revising the manuscript with a great care and precision.*

*I would like to express my gratitude to **Prof. Dr. Mohamed A. Ali** Professor of Virology, head of CSEIV (Center of Scientific Excellence of Influenza Viruses), Water Pollution Research Department, National Research Centre, for his guidance to my study and also to my life. I appreciated his technical and spiritual support throughout my whole study. Also, I sincerely thank him for his constant support, encouragement during the study. I learned a lot from him. I have enjoyed our discussions immensely. I also thank him for his thoughtful critiques. He is my second father absolutely.*

*I would like to thank **Dr. Ghazi Kayali** Associate Professor of Virology, Department of Epidemiology and Human Genetics - University of Texas, USA for his sincere guidance, generous help in all the theoretical and practical aspects and for building up the hypothesis related to the results.*

*My deepest thanks for all my colleagues, **Dr. A. Mostafa, Dr. A. Kandeil, Dr. R. Elshesheny, M. Gomaa, A. Elsayed, A. Nageh, S. Hussein, O. Bagato, Y. moatsem, A. Maatouk and Mohamed Elsayed** from CSEIV for their cooperation and help.*

Funding: *this work was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract number HHSN272201400006C.*

ABSTRACT

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) represents a global human health threat since its first zoonotic transmission to humans. Since 2012, a total of 2229 human confirmed infections with MERS-CoV were documented (791 fatalities; case-fatality rate=36%) in 27 countries. Herein, an active surveillance of MERS-CoV in Egypt among local and imported camels was conducted to demonstrate the prevalence situation and to characterize MERS-CoVs in Egypt. Subsequently, a well-characterized MERS-CoV isolate was used to develop vaccines via three different approaches; (1) DNA vaccines (encode structural proteins spike S, envelope E, membrane M and nucleocapsid N); (2) outer-membrane vesicles (OMVs)-based preparations expressing receptor-binding domain (RBD) of MERS-CoV spike protein; (3) a novel recombinant chimeric influenza A H1N1 pandemic (A/California/04/2009) (5+3) as a vector to express an immunogenic short peptide residue of MERS-CoV spike protein to elucidate immunity against MERS-CoV and H1N1pdm09. This study included the molecular characterization and serological analysis of 5693 samples. Interestingly, collected samples from camels have showed relatively high seropositivity for sera samples (71.2%). Nevertheless, for other types of collected samples which were tested by RT-PCR, the positivity rate was low and variable: nasal (15.4%), rectal (15.8%), milk (6.4%) and urine (0%). The imported camels showed higher percent in sera and viral prevalence than local one. The full genome sequences of Egyptian MERS-CoVs are grouped with a novel clade C out of clades A and B. Interestingly, the results of developed vaccine trials showed that BALB/c mice vaccinated with pcDNA3.1-S and pcDNA3.1-N gave potent neutralizing antibodies (nAbs) against MERS-CoV. The novel recombinant OMV-H1-RBD and the two chimeric rescued inactivated rgH1N1-peptide-MERS-CoVs stimulated a protective nAbs against H1N1pdm09 and MERS-CoV in vaccinated mice. This study is providing evidences that camels are the main reservoirs for MERS-CoV and surveillance in African exporting countries is urgently required. Also to control MERS-CoV, DNA vaccines of S and N encoded protein are highly recommended. The novel recombinant OMVs vaccine and two chimeric influenza virus with immunogenic peptide of MERS-CoV is can serve as effective bivalent vaccine to combat both H1N1pdm09 and MERS-CoV infections.

Keywords: MERS-CoV, surveillance, vaccine, and Egypt.

CONTENTS

	Page
INTRODUCTION	1
REVIEW OF LITERATURE	5
1. Middle East respiratory syndrome corona virus (MERS-CoV).....	5
1.1. Classification and nomenclature of MERS CoV.....	5
1.2. Structure and composition of MERS-CoV.....	5
1.3. Genome Structure and Gene Functions.....	7
1.4. MERS-CoV replication cycle.....	8
1.5. Epidemiology of MERS-CoV.....	11
1.6. MERS-CoV infected cases geographic distribution.....	12
1.7. Cases and clusters.....	13
1.8. Evolution of MERS-CoV	16
1.9. MERS-CoV origin of transmission	18
1.10. Sero-prevalence of MERS-CoV in camels.....	19
1.11. Transmission of MERS-CoV.....	20
1.12. Diagnosis of MERS-CoV	26
1.13. Control of MERS-CoV	27
1.14. Attempts of animal models for MERS-CoV infection.....	33
1.15. Influenza viruses as a viral vector for vaccination.....	38
1.16. Outer-membrane vesicles as a platform for vaccination.....	40
MATERIALS AND METHODS	42
1. Systematic active surveillance of MERS-CoV in dromedary camels in Egypt	
1.1. Sampling and location	42
1.2. Molecular testing	43
1.2.1. Viral RNA extraction	44
1.2.2. Detection of MERS-CoV.....	45
1.3. Virus isolation	51
1.3.1. Full genome amplification of MERS-CoV isolate	53
1.4. Serological testing	59
1.4.1. Viral Microneutralization Assay (MNA)	59
1.5. Statistical analysis	63
2. Approaches to develop MERS-CoV vaccines	63
2.1. DNA vaccine	63
2.1.1. Amplification of S, E, M and N genes	63
2.1.2. Cloning of S, E, M and N genes in pCDNA3.1 mammalian expression vector	66
2.1.3. Transformation	67
2.1.4. Structural S, E, M and N genes plasmid mini-preparation.....	68

2.1.5. DNA sequencing and sequence analysis	69
2.1.6. Large-scale preparation (Maxiprep) of plasmid DNA	69
2.1.7. Preparation of inactivated MERS-CoV (positive control) vaccine	70
2.1.8. DNA vaccine immunization to BALB/c mice	71
2.2. Outer-membrane vesicles (OMVs) Bivalent vaccine	73
2.2.1. Construction of pMP-H1-RBD/MERS-COV construct by recombinant ligation using restriction enzymes	73
2.2.2. Preparation of the OMVs from DH10B transformed with pMP-H1-RBD construct	75
2.2.3. Characterization of the viral proteins using western blot analysis (Semi-dry)	76
2.2.4. Mice immunization	78
2.2.5. Mice infection challenge	79
2.2.6. Hemagglutination Inhibition (HAI) assay (WHO, 2002) ..	79
2.2.7. PRNT assay	82
2.3. Development of inactivated rgH1N1-pdm09-MERS-CoV bivalent vaccine	82
2.3.1. Prediction of short peptides in MERS-CoV	82
2.3.2. Construction of PHW2000- NA17B-Peptide-MERS and PHW2000-NApdm09-Peptide-MERS by recombinant ligation	83
2.3.3. Rescue viruses (generation of recombinant viruses) by reverse genetic	90
2.3.4. Preparation of inactivated vaccine	92
2.3.5. Mice immunization	93
2.3.6. Mice infections	94
2.4. Statistical analysis.....	94
RESULTS	95
1. Systematic active surveillance of MERS-CoV in dromedary camels in Egypt	95
1.1. Molecular and serological results	95
1.2. Virus isolation	106
1.3. Full genome amplification of MERS-CoV	106
1.3.1. Phylogenetic analysis of MERS-CoV complete genome..	107
2. Approaches to develop MERS-CoV vaccines	109
2.1. DNA vaccines	109
2.1.1. Amplification of structural genes S, E, M and N	109
2.1.2. Purification and cloning of S, E, M and N in pCDNA3.1.	110
2.1.3. Evaluation of DNA vaccines in BALB/c mice	110
2.1.4. PRNT assay for mice sera against MERS-CoV	110
2.2. OMVs bivalent H1-RBD vaccine	114

2.2.1. Construction of recombinant pMP-H1-RBD-MERS-COV	114
2.2.2. Preparation of the OMVs from DH10B transformed bacteria	115
2.2.3. Characterization of the viral proteins using western blot analysis	116
2.2.4. Evaluation of recombinant OMVs-H1-RBD in BALB/c mice	117
2.2.5. HAI assay against rgH1N1pdm09	117
2.2.6. PRNT assay against MERS-CoV virus	118
2.2.7. Challenge infection with wild type H1N1pdm09	123
2.3. Bivalent chimeric rgH1N1-short peptide MERS-CoV vaccine ...	125
2.3.1. Prediction of short peptides in MERS-CoV	125
2.3.2. Construction of PHW2000-NA-17B-Peptide-MERS and PHW2000-NA-pdm09-Peptide-MERS by recombinant ligation	125
2.3.3. Amplification of fragments	126
2.3.4. Cloning of new NA gene into pHW2000	127
2.3.5. Development of reassortant rgH1N1-peptide-MERS candidate vaccine strains by reverse genetics	128
2.3.6. Evaluation of recombinant rgH1N1-Peptide-MERS-CoV vaccines in BALB/c mice	132
DISCUSSION	139
SUMMARY	149
REFERENCES	152
ARABIC SUMMARY	